[go: up one dir, main page]

WO2006122543A1 - Matieres minerales micronisees et leur production - Google Patents

Matieres minerales micronisees et leur production Download PDF

Info

Publication number
WO2006122543A1
WO2006122543A1 PCT/DE2006/000889 DE2006000889W WO2006122543A1 WO 2006122543 A1 WO2006122543 A1 WO 2006122543A1 DE 2006000889 W DE2006000889 W DE 2006000889W WO 2006122543 A1 WO2006122543 A1 WO 2006122543A1
Authority
WO
WIPO (PCT)
Prior art keywords
micronized
mineral material
natural mineral
treated
zeolites
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2006/000889
Other languages
German (de)
English (en)
Inventor
Tihomir Lelas
Mijo Ljubicic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE112006002042T priority Critical patent/DE112006002042A5/de
Publication of WO2006122543A1 publication Critical patent/WO2006122543A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C13/00—Disintegrating by mills having rotary beater elements ; Hammer mills
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B39/00—Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites; Their preparation; After-treatment, e.g. ion-exchange or dealumination
    • C01B39/02—Crystalline aluminosilicate zeolites; Isomorphous compounds thereof; Direct preparation thereof; Preparation thereof starting from a reaction mixture containing a crystalline zeolite of another type, or from preformed reactants; After-treatment thereof
    • C01B39/026—After-treatment

Definitions

  • the invention describes a device for fine grinding and micronizing mineral materials with a particle size distribution in the nanometer range using impact and friction processes.
  • the invention is based on the use of tribomechanically activated zeolites, in particular of natural micronized clinoptilolite.
  • a device which can crush zeolites in such a way that their effectiveness is improved is also already known from DE 197 55 921 A1.
  • the invention there describes a method for improving the effectiveness of active ingredients, which consist of at least mineral substances, by these active substances are subjected to a tribomechanical Activation devist, in which increases the surface area of the treated drugs and their structure is destabilized to increase the chemical potential.
  • the micronization to be achieved by the device known from DE 197 55 921 A1 is 20 p per particle, whereby only about 78% of all particles reach this order of magnitude.
  • DE 197 55 921 A1 describes a method for improving the effectiveness of minerals as active ingredients, by subjecting these active ingredients to tribomechanical activation, in which the surface of the treated active ingredients is increased and the structure of which is destabilized to increase the chemical potential.
  • the device described for this purpose has at least three rows of wreaths, which are driven in opposite directions, with blade-like projections (fan blades) being fastened on each row of wreaths.
  • the apparatus for fine grinding and micronizing of materials consists of a housing with two rotors, each having a plurality of intermeshing, oppositely driven at equal angular speed wreaths which are driven separately, and wherein the wreaths are hollow and in its interior a plurality of Wear fan blades fastened on both sides of the walls of the crane, which serve as a collision obstacle for the materials to be fine-ground and micronized, and wherein the materials due to the inside of the housing.
  • This prevailing centrifugal forces are transported from an inner wreath into an outer wreath.
  • the activation of the minerals is done by intervening in the integrity of the crystal lattice, resulting in a kind of damage, which in turn in the form of an activation, for example, electrical type, noticeable.
  • DE 197 55 921 A1 regards as advantageous the treatment of zeolites, which are described there for salutary consumption for humans; Also calcites for the agricultural sector are mentioned.
  • the disadvantages of DE 197 55 921.2 are as follows:
  • the micronization to be achieved by the known device is 20 ⁇ per particle, with only about 78% of all particles reaching this order of magnitude;
  • WO 00/64586 A1 likewise describes a device for micronizing, in which the rotors consist of disks on which the fan blades are arranged fixed on one side and wherein the fan blades are connected to the rings and engage in corresponding channels on the respectively opposite rotor disk, which prevent material passage under the fan blades.
  • the working tools of such devices are mainly pens or fan blades whose job it is to create an air vortex and to bring the fracture particles to mutual collisions and collisions with the tools through the controlled movement and control of the air streams, thereby increasing the responsiveness of the Material surface and changes in the structural stability of the material are brought about.
  • the mineral material preferably the clinoptilolite
  • the microenized material according to the invention is admixed with a pharmaceutically acceptable carrier or adjuvant. It was completely surprising that the micronized materials according to the invention, which can be used by the micronization in tribomechanically activated form templates to simply safely and effectively treat diseases that are associated with adverse or pathological oxidation processes of cells or cell tissues.
  • the material in the material according to the invention is tribomechanically activated zeolites.
  • M mono- or polyvalent metal (usually an alkali metal or alkaline earth cation), H or NH 4, etc.
  • z valence of a cation
  • x 1, 8 to about 12
  • y 0 to about 8.
  • the natural zeolites can be classified according to their crystal lattices into fiber zeolites, especially natrolite, laumontite, mordenite, thomsonite;
  • Leaf zeolites in particular heulandite, stilbite, phillipsite, harmotome and the cube zeolites, in particular faujasite, gmelinite, chabazite, offretite.
  • the feldspatids such as lapis lazuli and its related minerals, sodalite, nosean and hauyn, as well as the artificially produced ultramarine pigments, as well as the analcime, belong to the zeolites.
  • zeolite types are chabazite, clinoptilolite (a variety of heulandite), erionite and mordenite. Particularly preferred is clinoptilolite, which belongs to the zeolites of Heulanditen and is completely miscible with heulandite. According to the invention, in the case of heulandite, the ratio of silicon to aluminum in accordance with the invention, a mixture of clinoptilolite and heulandite can accordingly also be used instead of the kinoptilolite.
  • the compounds according to the invention comprise customary auxiliaries, preferably carriers, adjuvants and / or vehicles.
  • the carriers may be, for example, fillers, extenders, binders, humectants, disintegrants, dissolution inhibitors, absorption accelerators, wetting agents, adsorbents and / or lubricants.
  • the compounds are referred to in particular as drugs or pharmaceutical agents.
  • the inventive composition as a gel, powder, powder, tablet, sustained-release tablet, premix, emulsion, infusion formulation, drops, concentrate, granules, syrup, pellet, BoIi, capsule, aerosol, spray and or inhalant prepared and / or used in this form.
  • the tablets, dragees, capsules, pills and granules may be provided with the usual, optionally opacifying, containing coatings and shells and also be composed so that they deliver the active substance or only optionally delayed in a certain part of the intestinal tract, where as embedding masses, for example, polymer substances and waxes can be used.
  • the pharmaceutical compositions of this invention may be used for oral administration in any orally acceptable dosage form including, but not limited to, capsules, tablets, and aqueous suspensions and solutions.
  • carriers that are commonly used include lactose and corn starch.
  • Lubricants such as magnesium stearate, can typically be added.
  • useful diluents such as lactose and dried corn starch are used.
  • aqueous suspensions are administered orally, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and / or flavoring and / or coloring agents may be added.
  • the active substance (s) may optionally also be present in microencapsulated form with one or more of the excipients specified above.
  • Suppositories may in addition to the active substance contain the customary water-soluble or water-insoluble excipients, for example Polyethylenglyco- Ie, fats, for example cocoa fat and higher esters (for example C 14 alcohol with C 6 fatty acid) or mixtures of these substances.
  • Ointments, pastes, creams and gels may in addition to the active ingredient or the usual excipients include, for example, animal and vegetable fats, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonite te, silica, talc and zinc oxide or mixtures of these substances.
  • Powders and sprays may contain, in addition to the active substance (s), the usual excipients, for example lactose, talc, silicic acid, aluminum hydroxide, calcium silicate and polyamide powder or mixtures of these substances.
  • Sprays may additionally contain the usual propellants, for example chlorofluorocarbons.
  • Solutions and emulsions may, in addition to the active compounds, ie the compounds according to the invention, the customary carriers such as solvents, solubilizers and emulsifiers, for example water, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1, 3- Butylene glycol, dimethylformamide, oils, especially cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil, glycerol, glycerol formal, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan or mixtures of these substances.
  • the solutions and emulsions may also be present in sterile and blood isotonic form.
  • Suspensions may, in addition to the active ingredients, the usual carriers such as liquid diluents, for example water, ethyl alcohol, propylene glycol, suspending agents, for example ethoxylated Isostearylalkohole, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar and tragacanth or mixtures of these substances.
  • liquid diluents for example water, ethyl alcohol, propylene glycol
  • suspending agents for example ethoxylated Isostearylalkohole, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar and tragacanth or mixtures of these substances.
  • the pharmaceutical compositions may be in the form of a lyophilized sterile injectable preparation, for example as a sterile injectable aqueous or oily suspension.
  • This suspension can also be prepared by methods known in the art. of suitable dispersing or wetting agents (such as Tween 80) and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, a solution in 1,3-butanediol.
  • Compatible vehicles and solvents that may be used include mannitol, water, Ringer's solution and isotonic sodium chloride solution.
  • sterile non-volatile oils are commonly used as the solvent or suspending medium.
  • Any mild non-volatile oil including synthetic mono- or diglycerides may be used for this purpose.
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils such as olive oil or castor oil, especially in their polyoxyethylated forms.
  • These oil solutions or suspensions may also contain a long-chain alcohol or similar alcohol as a diluent or dispersant.
  • the formulation forms mentioned can also contain colorants, preservatives and odor and taste-improved additives, for example peppermint oil and eucalyptus oil, and sweeteners, for example saccharin.
  • the compounds according to the invention should preferably be present in the listed pharmaceutical preparations in a concentration of about 0.01 to 99.9, preferably of about 0.05 to 99,% by weight of the total mixture.
  • the listed pharmaceutical preparations may contain further pharmaceutically active substances, but in addition to other pharmaceutical active substances also salts, buffers, vitamins, sugar derivatives, in particular saccharides, enzymes, plant extracts and others.
  • the buffers and sugar derivatives advantageously reduce the pain on subcutaneous administration and enzymes increase the efficacy.
  • the preparation of the abovementioned pharmaceutical preparations is carried out in a customary manner by known methods, for example by mixing the active substance (s) with the excipient (s).
  • the preparations mentioned can be administered orally, rectally, parenterally (intravenously, intra-muscularly, subcutaneously) in humans and animals, intracisternally, intravaginally, intraperitoneally, locally (powder, ointment, drops) and for the therapy of those mentioned below Diseases are applied.
  • Suitable preparations are injection solutions, solutions and suspensions for oral therapy, gels, infusion formulations, emulsions, ointments or drops.
  • ophthalmic and dermatological formulations, silver and other salts, ear drops, eye ointments, powders or solutions may be used.
  • uptake can also take place via the feed or drinking water in suitable formulations.
  • the drugs can be incorporated into other carrier materials such as plastics - plastic chains for local therapy -, collagen or bone cement.
  • the compounds are introduced in a concentration of from 0.1 to 99.5, preferably from 0.5 to 95, particularly preferably from 20 to 80,% by weight in a pharmaceutical preparation. That is, the compounds are present in the pharmaceutical compositions listed above, for example, tablets, pills, granules, and others, preferably in a concentration of from 0.1% to 99.5% by weight of the total mixture.
  • the amount of active ingredient that is to say the amount of compounds of the invention combined with the carrier materials to produce a single dosage form, will be varied by one skilled in the art depending on the subject to be treated and the particular mode of administration. After improving the condition of the patient, the proportion of active compound in the preparation may be changed to provide a maintenance dose that arrests the disease.
  • the dose or frequency of administration, or both as a function of the symptoms may be reduced to a level at which the improved condition is maintained.
  • treatment should cease.
  • patients may require long-term discontinuous treatment after any recurrence of disease symptoms. Accordingly, the proportion of the compounds, that is to say their concentration, in the overall mixture of the pharmaceutical preparation as well as their composition or combination is variable and can be modified and adapted by the person skilled in the art on the basis of his specialist knowledge.
  • the compounds according to the invention are combined with an organism, preferably a human or an animal, in various ways. can be brought into contact. Furthermore, it is known to the person skilled in the art that, in particular, the pharmaceutical agents can be administered in various dosages.
  • the application should be carried out in such a way that the disease is combated as effectively as possible or the onset of a disease in a prophylactic administration is prevented. The concentration and the type of application can be determined by the skilled person through routine experimentation.
  • Preferred applications of the compounds according to the invention are oral administration in the form of powders, tablets, juice, drops, capsules or the like, rectal administration in the form of suppositories, solutions and the like, parenterally in the form of injections, infusions and solutions and locally in Form of ointments, patches, envelopes, rinses and the like.
  • the contacting of the compounds according to the invention preferably takes place prophylactically or therapeutically.
  • the suitability of the chosen forms of administration as well as the dose, the application scheme, the adjuvant choice and the like can be determined, for example, by removing serum aliquots from the patient, ie human or animal, and testing for the presence of disease indicators during the course of the disease Treatment protocol can be determined.
  • the condition of the kidneys, the liver, etc., but also the amount of T cells or other cells of the immune system can be determined concomitantly in a conventional manner to provide a general view of the immunological constitution of the patient and in particular the constitution of metabolically important Organs to get.
  • the patient's clinical condition can be monitored for the desired effect. If inadequate therapeutic efficacy is achieved, the patient may be further treated with agents of the invention modified with other known drugs of which an improvement in overall constitution can be expected.
  • injections for example intramuscularly or subcutaneously or into the blood vessels
  • injections are a further preferred route for the therapeutic administration of the compounds according to the invention.
  • the delivery via catheters or surgical tubes can be used; for example, via catheters directly to certain organs such as the kidneys, liver, spleen, intestine, lungs, etc.
  • the compounds according to the invention can be used in a preferred embodiment in a total amount of preferably 0.005 to 500 mg / kg of body weight per 24 hours, preferably from 1 to 10 mg / kg of body weight. This is advantageously a therapeutic amount used to prevent or ameliorate the symptoms of a disorder or responsive, pathologically physiological condition.
  • the dose will depend on the age, the health and weight of the recipient, the degree of the disease, the nature of a necessary concomitant treatment, the frequency of treatment and the nature of the effects desired and the side effects.
  • the daily dose of 0.005 to 500 mg / kg body weight may be used once or several times to obtain the desired results.
  • pharmaceutical agents are used for about 1 to 10 times a day or alternatively or additionally as a continuous infusion.
  • Such administrations can be used as a chronic or acute therapy.
  • the amounts of drug combined with the carrier materials to produce a single dosage form may vary depending on the host to be treated and the particular mode of administration.
  • the daily dose it is preferred to distribute the daily dose to 2 to 5 applications, wherein for each application, for example, 1 to 2 tablets are administered with an active ingredient content of 0.005 to 500 mg / kg body weight.
  • the active ingredient content also higher, for example up to a concentration of up to 5000 mg / kg.
  • the tablets may also be retarded, reducing the number of applications per day to 1 to 3.
  • the active ingredient content of the delayed-release tablets can be 3 to 3000 mg.
  • the active ingredient is administered by injection, it is preferred to contact the host with the compounds of the invention 1 to 10 times a day or by continuous infusion, with amounts of 1 to 4000 mg per day being preferred.
  • the preferred total amounts per day have proven beneficial in human and veterinary medicine.
  • the pharmaceutical agent is used in a single dose of 1 to 100, in particular from 2 to 50 mg / kg of body weight.
  • the amount of the single dose per application can also be varied by the person skilled in the art on the basis of his specialist knowledge.
  • the compounds used according to the invention can also be used in veterinary medicine in the individual concentrations and preparations mentioned together with the feed or with feed preparations or with the drinking water.
  • a single dose preferably contains the amount of active ingredient administered in one application, which usually corresponds to a whole, a half daily dose or a third or a quarter of a daily dose.
  • the dosage units may accordingly preferably contain 1, 2, 3 or 4 or more single doses or 0.5, 0.3 or 0.25 of a single dose.
  • the daily dose of the compounds according to the invention is preferably distributed over 2 to 10 applications, preferably 2 to 7, more preferably 3 to 5 applications. Of course, a continuous infusion of the compositions of the invention is possible.
  • 1 to 10 tablets are given for each oral application of the compounds according to the invention.
  • the tablets according to the invention may be provided with coatings and casings known to the person skilled in the art and may also be composed in such a way that they release the active ingredient or agents only in preferred manner, in a specific part of the host.
  • the individual constituents of the compounds optionally associated with each other or with a carrier enclosed in liposomes are included, wherein the inclusion in liposomes according to the invention does not necessarily mean that the compounds are present in the interior of the liposomes.
  • An inclusion in the sense of the invention may also mean that the compounds are associated with the membrane of the liposomes, for example, so that they are anchored on the outer membrane.
  • Such a representation of the compounds according to the invention in or on the liposomes is advantageous if the person skilled in the art selects the liposomes in such a way that they have an immunostimulating action.
  • DE 198 51 2 82 discloses various possibilities for the skilled person to modify the immunostimulating action of liposomes.
  • the lipids may be simple lipids such as esters and amides or complex lipids such as glycolipids such as cerebrosides or gangliosides, sphingolipids or phospholipids.
  • Preferred diseases which are associated with modified or pathological oxidation processes and which accordingly can be treated according to the invention are selected from the group comprising: AIDS, acne, albuminuria (proteinuria), alcohol withdrawal syndrome, allergies, alopecia (hair loss), ALS (amyotrophs Lateral sclerosis), Alzheimer's disease, AMD (age-related macular degeneration), anemia, anxiety disorders, anthrax, aortic sclerosis, arterial occlusive disease, arteriosclerosis, arterial occlusion, temporal arteritis, atherosclerosis, arteriovenous fistulas, arthritis, osteoarthritis, asthma, respiratory insufficiency, autoimmune disease, AV Block, acidosis, herniated disc, peritonitis, pancreatic cancer, Becker muscular dystrophy, benign prostatic hyperplasia (BPH), bladder carcinoma, haemophilia, bronchial carcinoma, breast cancer, BSE, Budd-Chiari syndrome, bulimia nervosa, burs
  • agents according to the invention in particular the pharmaceutical compositions comprising them, have various advantages.
  • the particles according to the invention ie tribo-mechanically comminuted material can be obtained with a rotary mill, which is completely housed in a hermetically insulated vessel so that the air sucked off and a dilute atmosphere can be created up to the vacuum.
  • the fact that it is possible to generate material according to the invention with such a device is therefore surprising, since it does not seem sufficient to replace only the comminution unit under vacuum. With such devices no particles according to the invention are obtained.
  • the refining atmosphere alone at the site of direct milling does not seem critical since, quite surprisingly, the entire apparatus must be placed under vacuum.
  • the device according to the invention accordingly provides an improved device for micronizing minerals and other material which has a higher efficiency of micronization. In addition to the micronization is also the Process of tribomechanical treatment and the associated activation of the natural material under vacuum or dilute atmosphere instead.
  • the material micronized by the device according to the invention has many advantages for a wide variety of uses.
  • the novel device causes diverse chemical and chemical-physical changes in mineral raw material components.
  • the effects created by dynamic friction processes give these minerals new properties that can be used technologically and commercially in the manufacture of diverse products.
  • the treated material influences the rate of oxidation of ascorbates with the nitrobenes. This also happens in the physiological range of 50/50 dioxane water.
  • the acceleration of the reactions in the acidic region occurs as a result of: a) change in the pH system under the action of the treated material b) molecular interaction of ascorbic acid with the Gouy layer on the granules of the material due to the change in rate constants due to the Dissociation of ascorbic acid happen.
  • the treated zeolite adsorbs karbo cations in the medium without water. A corresponding similar effect of the untreated material is not detectable.
  • the experimental setup consisted of two glass containers, each filled with 200 ml of Kunststoff tap water whose redox potential was +170 m u in both containers. 1 gram of zeolite powder was added to each container, with:
  • crushed zeolite (1 gram) was placed in the other container
  • Fig. 1 shows a cross section through a device according to the invention for micronization
  • Fig. 2 is a detail view of a blade
  • the manual valve (d) is used to let in the inert gas or for davacuuming after the material container (4) has been disconnected from the system.
  • the motorized valve (s) closes the container piping system after activation is complete.
  • the valves c and e are open.
  • the valve d is closed.
  • the valve c is closed.
  • the activator is switched on, the auger dispenser is switched on and the material is activated.
  • the valve e closes, the devacuuming takes place, the door opens, and the car is pulled out on the outer cart.
  • the material container is decacuumed through the valve d, or inert gas is allowed to enter the container through this valve.
  • FIG. 2 shows in detail a blade according to the invention.
  • the activator 6 with which the material is treated, there are some discs with blades. The discs rotate in opposite directions, causing the material to be highly fluidized, causing collisions on the blades that ultimately result in the material being shredded and activated.
  • the attack surface of the blade is inventively created from a Synthetikru- bin platelets. The plate is attached to the blade carrier.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geology (AREA)
  • Food Science & Technology (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Matière minérale naturelle micronisée, de préférence clinoptilolithe, qui possède une taille des grains inférieure à 100 nm, et procédés de micronisation de matière minérale naturelle, en particulier de clinoptilolithes, la micronisation étant effectuée dans un moulin rotatif se trouvant sous vide ou dans une atmosphère raréfiée. La présente invention concerne également l'utilisation de ladite matière minérale naturelle micronisée.
PCT/DE2006/000889 2005-05-18 2006-05-18 Matieres minerales micronisees et leur production Ceased WO2006122543A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE112006002042T DE112006002042A5 (de) 2005-05-18 2006-05-18 Mikronisierte mineralische Materialien und deren Herstellung

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005023503 2005-05-18
DE102005023503.4 2005-05-18

Publications (1)

Publication Number Publication Date
WO2006122543A1 true WO2006122543A1 (fr) 2006-11-23

Family

ID=36763688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2006/000889 Ceased WO2006122543A1 (fr) 2005-05-18 2006-05-18 Matieres minerales micronisees et leur production

Country Status (2)

Country Link
DE (1) DE112006002042A5 (fr)
WO (1) WO2006122543A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20090987A1 (it) * 2009-06-05 2010-12-06 Hf Europ Srl Prodotti alimentari comprendenti zeoliti
ITRM20100435A1 (it) * 2010-08-03 2012-02-04 Ecobase Gmbh Zeoliti ad azione neuroprotettiva

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB638673A (en) * 1946-07-03 1950-06-14 Sarl Improvements in crushing machines
WO1982003572A1 (fr) * 1981-04-13 1982-10-28 Bjoerck Conny Procede de concassage fin de particules de materiaux dans un broyeur centrifuge et dispositif permettant d'executer ce procede
DE4014120A1 (de) * 1990-05-02 1991-11-07 Tatabanyai Banyak Vallalat Verfahren und vorrichtung zur zerkleinerung nicht-metallischer mineralien
DE10002054A1 (de) * 2000-01-19 2001-07-26 Reiner Weichert Vorrichtung und Verfahren zur Ultrafeinmahlung fester Stoffe auf Partikelgrößen im Nanometerbereich
DE10323759A1 (de) * 2003-05-22 2004-12-16 Bauer, Wulf, Dr. Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen
US20050002970A1 (en) * 2001-12-21 2005-01-06 Ketelson Howard Allen Inorganic nanopartices to modify the viscosity and physical properties of ophthalmic and otic compositions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB638673A (en) * 1946-07-03 1950-06-14 Sarl Improvements in crushing machines
WO1982003572A1 (fr) * 1981-04-13 1982-10-28 Bjoerck Conny Procede de concassage fin de particules de materiaux dans un broyeur centrifuge et dispositif permettant d'executer ce procede
DE4014120A1 (de) * 1990-05-02 1991-11-07 Tatabanyai Banyak Vallalat Verfahren und vorrichtung zur zerkleinerung nicht-metallischer mineralien
DE10002054A1 (de) * 2000-01-19 2001-07-26 Reiner Weichert Vorrichtung und Verfahren zur Ultrafeinmahlung fester Stoffe auf Partikelgrößen im Nanometerbereich
US20050002970A1 (en) * 2001-12-21 2005-01-06 Ketelson Howard Allen Inorganic nanopartices to modify the viscosity and physical properties of ophthalmic and otic compositions
DE10323759A1 (de) * 2003-05-22 2004-12-16 Bauer, Wulf, Dr. Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20090987A1 (it) * 2009-06-05 2010-12-06 Hf Europ Srl Prodotti alimentari comprendenti zeoliti
WO2010140034A3 (fr) * 2009-06-05 2011-01-27 Hf Europe S.R.L. Produits alimentaires comprenant des zéolithes
CN102458158A (zh) * 2009-06-05 2012-05-16 Hf欧洲有限公司 包含沸石的食品
CN102458158B (zh) * 2009-06-05 2016-03-16 Hf欧洲有限公司 包含沸石的食品
ITRM20100435A1 (it) * 2010-08-03 2012-02-04 Ecobase Gmbh Zeoliti ad azione neuroprotettiva

Also Published As

Publication number Publication date
DE112006002042A5 (de) 2008-04-30

Similar Documents

Publication Publication Date Title
DE2660069C2 (fr)
DE60020732T2 (de) Verfahren zur herstellung von nanometer partikeln durch fliessbett- sprühtrocknung
DE69330724T2 (de) Antitumorzusammensetzungen enthaltend Taxanderivate
DE2950977C2 (fr)
DE69532469T2 (de) Adhäsion inhibierender Vaccinium Extrakt
DE2437845A1 (de) Pharmazeutisches, dispergierbares, sitosterine enthaltendes pulver und verfahren zu seiner herstellung
EP1316530A1 (fr) Zeolithes micronisées destinés à être utilisés comme préparations pharmaceutiques
EP4408374A1 (fr) Particules de charbon actif a prétraitées mécanochimiquement exemptes de métaux lourds, médicaments topiques, produits médicinaux et produits cosmétiques, procédé de production et utilisations
EP2538950B1 (fr) Préparations à base de zéolite contenant de la clinoptilolite et leurs applications
WO2006122543A1 (fr) Matieres minerales micronisees et leur production
WO2007054085A2 (fr) Zeolithe active de maniere tribomecanique, utilise comme agent antiviral et son utilisation
EP2139505B1 (fr) Nouvelle composition pharmaceutique pour une utilisation comme laxatif
EP1628671A1 (fr) Pierre pulverisee, en particulier medicament a base de poudre de dolomie, pour traiter des pathologies cancereuses
EP1524986B1 (fr) Nanocomposes de clusters metalliques destines au traitement de maladies tumorales
DE102021004905A1 (de) Mechanochemisch vorbehandelte, schwermetallfreie Aktivkohlepartikel A
DE3609005A1 (de) Pharmazeutische zusammensetzungen mit metabolischer aktivitaet
EP2854823B1 (fr) Minéral argileux destiné à réduire les phosphates inorganiques, en particulier dans le cadre d'une thérapie de substitution rénale
DE2715384B2 (de) Arzneimittel gegen Diarrhöen
WO1994025473A1 (fr) Procede et dispositif de preparation du sel de sodium d'adn
WO2010052242A1 (fr) Procédé de concentration de substances bioactives issues de plantes utilisant des minéraux et formant des systèmes composites biominéraux réversibles
WO2006122541A2 (fr) Composition d'action pharmaceutique destinee au traitement de diabetes
EP2292105B1 (fr) Agent diététique
EP1839666A1 (fr) Composition pour traiter l'hypertension comprenant des zeolites activés tribomécaniquement
EP1640012A1 (fr) Agents pharmaceutiques comprenant des constituants du sang 10 kDa et l'utilisation dans la prophylaxe et dans le traitement des troubles du système immunitaire
DD249634A1 (de) Cholesterolsenkendes mittel und verfahren zu seiner herstellung

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 1120060020420

Country of ref document: DE

REF Corresponds to

Ref document number: 112006002042

Country of ref document: DE

Date of ref document: 20080430

Kind code of ref document: P

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: FESTSTELLUNG EINES RECHTSVERLUSTS NACH REGEL 112(1) EPUE

122 Ep: pct application non-entry in european phase

Ref document number: 06742368

Country of ref document: EP

Kind code of ref document: A1